Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 14% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-06-16. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: celllymphomatransplantheartfailure
  Phrases that lowered it: aminotransferaseclinicalpatientshepaticinvestigator
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past termination rate: 8.2% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 91 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 316 (lowers risk) · Sponsor's track record
• Collaborators: 2 (lowers risk) · Design
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 25.3% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports marked serious: 63.0% (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer NCT01942837 · started 2013 · scored riskier than 82% of active trials completed
• Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies NCT01974765 · started 2013 · scored riskier than 26% of active trials completed
• Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) NCT04692155 · started 2021 · scored riskier than 99% of active trials terminated
• Study of LY2835219 for Mantle Cell Lymphoma NCT01739309 · started 2013 · scored riskier than 41% of active trials completed
• Enzalutamide + External Beam Rt For Prostate NCT02028988 · started 2014 · scored riskier than 98% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.